TY - JOUR
T1 - Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer
T2 - Results from cancer and leukemia group B 150005/9480
AU - Humphrey, Peter A.
AU - Halabi, Susan
AU - Picus, Joel
AU - Sanford, Ben
AU - Vogelzang, Nicholas J.
AU - Small, Eric J.
AU - Kantoff, Philip W.
N1 - Funding Information:
The research for CALGB 150005 was supported in part by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman) and also by a grant from the T. J. Martell Foundation for Leukemia, Cancer, and AIDS Research. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. The following institutions participated in this study: CALGB Statistical Center, Durham, NC, Stephen George, PhD, supported by CA33601; Dana-Farber Cancer Institute, Boston, MA, George P. Canellos, MD, supported by CA32291; Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH, Marc S. Ernstoff, MD, supported by CA04326; Duke University Medical Center, Durham, NC, Jeffrey Crawford, MD, supported by CA47577; Mount Sinai School of Medicine, New York, NY, Lewis R. Silverman, MD, supported by CA04457; Roswell Park Cancer Institute, Buffalo, NY, Ellis Levine, MD, supported by CA02599; State University of New York, Upstate Medical University, Syracuse, NY, Stephen L. Graziano, MD, supported by CA21060; Ohio State University Medical Center, Columbus, OH, Clara D. Bloomfield, MD, supported by CA77658; University of California at San Diego, San Diego, CA, Stephen L. Seagren, MD, supported by CA11789; University of California at San Francisco, San Francisco, CA, Alan P. Venook, MD, supported by CA60138; University of Chicago Medical Center, Chicago, IL, Gini Fleming, MD, supported by CA41287; University of Illinois Minority-Based Community Clinical Oncology Program, Chicago, IL, Lawrence E. Feldman, MD, supported by CA74811; University of Iowa, Iowa City, IA, Gerald Clamon, MD, supported by CA47642; University of Maryland Greenebaum Cancer Center, Baltimore, MD, Martin Edelman, MD, supported by CA31983; University of Minnesota, Minneapolis, MN, Bruce A. Peterson, MD, supported by CA16450; University of Missouri/Ellis Fischel Cancer Center, Columbia, MO, Michael C. Perry, MD, supported by CA12046; University of Nebraska Medical Center, Omaha, NE, Anne Kessinger, MD, supported by CA77298; University of North Carolina at Chapel Hill, Chapel Hill, NC, Thomas C. Shea, MD, supported by CA47559; University of Tennessee at Memphis, Memphis, TN, Harvey B. Niell, MD, supported by CA47555; Vermont Cancer Center, Burlington, VT, Hyman B. Muss, MD, supported by CA77406; Wake Forest University School of Medicine, Winston-Salem, NC, David D. Hurd, MD, supported by CA03927; Walter Reed Army Medical Center, Washington, DC, Joseph J. Drabeck, MD, supported by CA26806. The authors thank Xiaopei Zhu for excellent technical assistance.
PY - 2006/3
Y1 - 2006/3
N2 - Background: Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostate carcinoma. Patients and Methods: Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate cancer enrolled in CALGB 9480 were quantified by solid-phase, enzyme-linked immunosorbent assay. Results: The Cox proportional hazards model was used to assess the prognostic importance of SF/HGF with adjustment for established prognostic factors. Median SF/HGF was 991 pg/mL (range, 212-2733 pg/mL). In a univariate analysis, although plasma SF/HGF levels above versus below the median value did not reach statistical significance (P = 0.0862), the cutoff point of > 935 pg/mL was associated with a significant reduction in overall survival (P = 0.0334). Patients with SF/HGF levels > 935 pg/mL experienced a median survival of 15 months compared with 19 months for men with SF/HGF levels ≤ 935 pg/mL. In a multivariate analysts, adjusting for SF/HGF, prostate-specific antigen, lactate dehydrogenase, and performance status, only plasma alkaline phosphatase was significantly associated with overall survival (hazard ratio, 1.7; 95% confidence interval, 1.2-2.5; P = 0.0017). Conclusion: Higher plasma levels of SF/HGF in men with hormone-refractory prostate cancer are associated with a decreased patient survival. Currently, SF/HGF levels do not appear to be of value as a contributor to multivariate models for prediction of outcome, but the association with decreased survival suggests that SF/HGF might be a potential target for therapy.
AB - Background: Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostate carcinoma. Patients and Methods: Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate cancer enrolled in CALGB 9480 were quantified by solid-phase, enzyme-linked immunosorbent assay. Results: The Cox proportional hazards model was used to assess the prognostic importance of SF/HGF with adjustment for established prognostic factors. Median SF/HGF was 991 pg/mL (range, 212-2733 pg/mL). In a univariate analysis, although plasma SF/HGF levels above versus below the median value did not reach statistical significance (P = 0.0862), the cutoff point of > 935 pg/mL was associated with a significant reduction in overall survival (P = 0.0334). Patients with SF/HGF levels > 935 pg/mL experienced a median survival of 15 months compared with 19 months for men with SF/HGF levels ≤ 935 pg/mL. In a multivariate analysts, adjusting for SF/HGF, prostate-specific antigen, lactate dehydrogenase, and performance status, only plasma alkaline phosphatase was significantly associated with overall survival (hazard ratio, 1.7; 95% confidence interval, 1.2-2.5; P = 0.0017). Conclusion: Higher plasma levels of SF/HGF in men with hormone-refractory prostate cancer are associated with a decreased patient survival. Currently, SF/HGF levels do not appear to be of value as a contributor to multivariate models for prediction of outcome, but the association with decreased survival suggests that SF/HGF might be a potential target for therapy.
KW - NK4
KW - Prognosis
KW - Suramin
KW - c-Met
UR - http://www.scopus.com/inward/record.url?scp=33646862208&partnerID=8YFLogxK
U2 - 10.3816/CGC.2006.n.006
DO - 10.3816/CGC.2006.n.006
M3 - Article
C2 - 16729910
AN - SCOPUS:33646862208
SN - 1558-7673
VL - 4
SP - 269
EP - 274
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 4
ER -